Company profile: Viela Bio
1.1 - Company Overview
Company description
- Provider of clinical-stage treatments for severe inflammation and autoimmune diseases, with a portfolio that selectively targets shared critical pathways at the root cause of disease; led by global leaders in inflammation and autoimmunity.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Viela Bio
Encycle Therapeutics
HQ: Canada
Website
- Description: Provider of a platform technology for rapid synthesis of drug-like macrocycles and membrane-permeable nacellins, which have potential to target intracellular protein-protein interactions largely intractable to small molecule and biologic modulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Encycle Therapeutics company profile →
TRex Bio
HQ: United States
Website
- Description: Provider of a deep biology platform that maps human tissue regulatory T cell behavior to disease using high-resolution sequencing, computational biology and translational assays to identify targets, and developer of therapeutics for cancer, fibrotic and immune-mediated diseases, including TRB-061 (TNFR2 agonist; IND-enabling, FIH 2025), TRB-031/-041 (with Eli Lilly; lead optimization) and TRB-071/-081 (target ID/validation).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TRex Bio company profile →
Blade Therapeutics
HQ: United States
Website
- Description: Provider of discovery-stage drug development focused on oral, small-molecule therapies for fibrotic and neurodegenerative diseases, including cudetaxestat—a Phase 2-ready, non-competitive autotaxin inhibitor for idiopathic pulmonary fibrosis; BLD-2184—an IND-ready candidate for neurodegenerative diseases; a class of autotaxin inhibitors; and calpain inhibitors targeting dimeric calpains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blade Therapeutics company profile →
Sigyn Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic technologies for inflammatory diseases, including Sigyn Therapy, a blood purification technology extracting pathogens and inflammatory mediators for endotoxemia, sepsis, and drug-resistant infections; ChemoPrep to enhance chemotherapy delivery by depleting tumor-derived extracellular vesicles; ChemoPure to reduce toxicity by removing off-target agents; and ImmunePrep to boost antibody-based immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigyn Therapeutics company profile →
Cellenkos
HQ: United States
Website
- Description: Provider of clinical-stage allogeneic cord blood regulatory T cell therapeutics for autoimmune and inflammatory disorders, enabled by the proprietary CRANE platform for cell enrichment and differentiation and in-house cGMP manufacturing. Pipeline includes CK0801 for bone marrow failure syndromes, CK0802 for COVID-19 ARDS, and CK0804 for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellenkos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Viela Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Viela Bio
2.2 - Growth funds investing in similar companies to Viela Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Viela Bio
4.2 - Public trading comparable groups for Viela Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →